IMM 13.2% 29.5¢ immutep limited

Overnight Market report, page-1489

  1. 2,546 Posts.
    lightbulb Created with Sketch. 301
    Initial accelerated approval was interestingly given on a 174 patient trial,our current combo trial has 154 patients.

    “The FDA granted accelerated approval based on early data from 174 patients with HNSCC enrolled in the nonrandomized KEYNOTE-012 trial”.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.